2015 American Transplant Congress
Identification of Mouse Tolerogenic B Cells Expressing PD-L1/PD-L2 in B-1a Subset
Donor lymphocyte infusion (DLI) has been shown to induce donor-specific hyporesponsiveness or even immune-tolerance among alloreactive T cells in different organ transplantation models. However, the…2015 American Transplant Congress
Long Term Outcomes of Tocilizumab Therapy for DSA+ Antibody Mediated Rejection (ABMR) Resistant to IVIG + Rituxan (I+R) Treatment
Intro: Limited options are available for treatment of ABMR in highly-HLA sensitized patients (HS). Treatment options include I+R, PLEX+I+/- R, C5-inhibitor & bortezomib. Approximately 25%…2015 American Transplant Congress
Epstein Barr Virus Modulates Host Cell MicroRNA-194 to Promote IL-10 Production in B Cell Lymphomas
Surgery/Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA.
Epstein Barr virus (EBV) infection is associated with the development of post-transplant lymphoproliferative disorder (PTLD) which can manifest as aggressive B cell lymphomas in transplant…2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…2015 American Transplant Congress
B Cell MicroRNA as Biomarkers for Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder
Surgery/Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA.
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of organ transplantation and is commonly associated with Epstein Barr virus (EBV) infection. EBV viral loads…2015 American Transplant Congress
Characterization of a Nude Mouse Model of Allosensitization Conditioned by Adoptive Transfer of Follicular T Helper Cells
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Follicular T helper (Tfh) cells play a critical role in follicular B cell activation and maturation during antibody responses to allograft. Here we report…2015 American Transplant Congress
Noncanonical Anergic Alloreactive B Cells in Transplantation Tolerance
Depart of Surgery, University of Chicago, Chicago.
The observation that operationally tolerant patients (TOL) display higher numbers of blood B cells and a B cell gene signature compared to stable kidney allograft…2015 American Transplant Congress
B-Cell Tolerance to Donor Alloantigens
Pre-existing panel-reactive antibodies and development of donor-specific alloantibodies are known to play important roles in graft dysfunction and deterioration. Preventing and/or eliminating alloantibody responses would…2015 American Transplant Congress
Preemptive Rituximab Therapy of Epstein-Barr Virus (EBV) Infection to Prevent Post-Transplant Lymphoproliferative Disease (PTLD) After Pediatric Solid Organ Transplantation (SOT)
Purpose: More than 90% of pediatric PTLD after solid organ transplantation is associated with EBV infection. Reduction in immunosuppression is the first step to prevent…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- 35
- Next Page »